论文信息 - Dianhydrogalactitol (NSC-132313): phase II study in solid tumors. - 字舞流文

Dianhydrogalactitol (NSC-132313): phase II study in solid tumors.

F. Cavalli | H. Hansen | A. Brugarolas | A. Clarysse | P. Alberto | R. D. De Jager | Y. Kenis | P. Siegenthaler | J. Renard | H. Ryssel

[1] F. Cavalli,et al. Phase II study of anhydro-ara-5-fluorocytidine in adenocarcinoma of gastrointestinal tract, epidermoid carcinoma of lung, head and neck, breast carcinoma and small cell anaplastic carcinoma of lung. A study report of the E.O.R.T.C. early clinical trial cooperative group. , 1978, European journal of cancer.

[2] D. Áfra,et al. Uptake of labeled dianhydrogalactitol into human gliomas and nervous tissue. , 1977, Cancer treatment reports.

[3] B. Hoogstraten,et al. Phase I evaluation of dianhydrogalactitol (NSC-132313). , 1976, Cancer treatment reports.

[4] B. Abbott,et al. A mouse ependymoblastoma as an experimental model for screening potential antineoplastic drugs. , 1974, Cancer chemotherapy reports. Part 2.

[5] Z. Szentirmay,et al. Pharmacologic and antitumor effects of 1,2:5,6-dianhydrogalactitol (NSC-132313). , 1972, Cancer chemotherapy reports.

[6] S. Eckhardt,et al. Metabolic pathway of cytostatic dibromohexitols. , 1967, Cancer chemotherapy reports.